Current Report Filing (8-k)
January 13 2020 - 11:21AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2020
Zymeworks Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
British Columbia, Canada
|
|
001-38068
|
|
47-2569713
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada
|
|
V6H 3V9
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(604) 678-1388
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Shares, no par value per share
|
|
ZYME
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 7.01
|
REGULATION FD DISCLOSURE
|
On January 12, 2020, Zymeworks Inc. issued a press release announcing the initiation of a Phase 2 trial evaluating ZW25
combination therapy and an agreement with Pfizer which advances the study. On January 13, 2020, this press release was filed with the Canadian securities regulatory authorities in Canada on the System for
Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com. A copy of this press release is attached as exhibit 99.1 hereto.
On
January 13, 2020, Zymeworks Inc. issued a press release highlighting its key accomplishments in 2019, providing updated corporate priorities, and announcing multiple clinical program advances for its lead candidates, ZW25 and ZW49. On
January 13, 2020, this press release was filed with the Canadian securities regulatory authorities in Canada on SEDAR at www.sedar.com. A copy of this press release is attached as exhibit 99.2 hereto.
The information provided under this Item (including exhibits 99.1 and 99.2, attached hereto) shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ZYMEWORKS INC.
|
|
|
|
|
(Registrant)
|
|
|
|
|
Date: January 13, 2020
|
|
|
|
By:
|
|
/s/ Neil A. Klompas
|
|
|
|
|
Name:
Title:
|
|
Neil A. Klompas
Executive Vice President,
Business
Operations and Chief Financial Officer
|
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Feb 2024 to Mar 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Mar 2023 to Mar 2024